Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Bioorg Med Chem ; 21(17): 5029-38, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23890524

ABSTRACT

Probes for use in time-resolved fluorescence competitive binding assays at melanocortin receptors based on the parental ligands MSH(4), MSH(7), and NDP-α-MSH were prepared by solid phase synthesis methods, purified, and characterized. The saturation binding of these probes was studied using HEK-293 cells engineered to overexpress the human melanocortin 4 receptor (hMC4R) as well as the human cholecystokinin 2 receptor (hCCK2R). The ratios of non-specific binding to total binding approached unity at high concentrations for each probe. At low probe concentrations, receptor-mediated binding and uptake was discernable, and so probe concentrations were kept as low as possible in determining Kd values. The Eu-DTPA-PEGO-MSH(4) probe exhibited low specific binding relative to non-specific binding, even at low nanomolar concentrations, and was deemed unsuitable for use in competition binding assays. The Eu-DTPA-PEGO probes based on MSH(7) and NDP-α-MSH exhibited Kd values of 27±3.9nM and 4.2±0.48nM, respectively, for binding with hMC4R. These probes were employed in competitive binding assays to characterize the interactions of hMC4R with monovalent and divalent MSH(4), MSH(7), and NDP-α-MSH constructs derived from squalene. Results from assays with both probes reflected only statistical enhancements, suggesting improper ligand spacing on the squalene scaffold for the divalent constructs. The Ki values from competitive binding assays that employed the MSH(7)-based probe were generally lower than the Ki values obtained when the probe based on NDP-α-MSH was employed, which is consistent with the greater potency of the latter probe. The probe based on MSH(7) was also competed with monovalent, divalent, and trivalent MSH(4) constructs that previously demonstrated multivalent binding in competitive binding assays against a variant of the probe based on NDP-α-MSH. Results from these assays confirm multivalent binding, but suggest a more modest increase in avidity for these MSH(4) constructs than was previously reported.


Subject(s)
Fluorescent Dyes/chemical synthesis , Receptors, Melanocortin/metabolism , Binding, Competitive , Fluorescent Dyes/chemistry , Fluorescent Dyes/metabolism , HEK293 Cells , Humans , Pentetic Acid/chemistry , Peptides/chemical synthesis , Peptides/chemistry , Peptides/metabolism , Protein Binding , Receptor, Cholecystokinin B/chemistry , Receptor, Cholecystokinin B/genetics , Receptor, Cholecystokinin B/metabolism , Receptor, Melanocortin, Type 4/chemistry , Receptor, Melanocortin, Type 4/genetics , Receptor, Melanocortin, Type 4/metabolism , Receptors, Melanocortin/chemistry , Solid-Phase Synthesis Techniques
2.
ACS Med Chem Lett ; 4(1): 98-102, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23524643

ABSTRACT

In order to develop agents for early detection and selective treatment of melanomas, high affinity and high specificity molecular tools are required. Enhanced specificity may be obtained by simultaneously binding to multiple cell surface targets via the use of multimeric analogs of naturally occurring ligands. Trimers targeting overexpressed melanocortin receptors have been found to be potential candidates for this purpose. In the present letter, we describe the synthesis and study of multimers based on a dendrimer-like scaffold. The binding affinity and activity results revealed that dendrimers promote multivalent interactions via statistical and/or cooperative effects on binding. Moreover, viability studies showed no significant toxicity at micromolar concentrations, which will allow these molecular complexes to be used in vivo. Finally, imaging studies showed effective internalization for all the molecules confirming their potential as delivery agents.

3.
Bioorg Med Chem Lett ; 23(8): 2422-5, 2013 Apr 15.
Article in English | MEDLINE | ID: mdl-23489620

ABSTRACT

In the quest for novel tools for early detection and treatment of cancer, we propose the use of multimers targeting overexpressed receptors at the cancer cell surface. Indeed, multimers are prone to create multivalent interactions, more potent and specific than their corresponding monovalent versions, thus enabling the potential for early detection. There is a lack of tools for early detection of pancreatic cancer, one of the deadliest forms of cancer, but CCK2-R overexpression on pancreatic cancer cells makes CCK based multimers potential markers for these cells. In this Letter, we describe the synthesis and evaluation of CCK trimers targeting overexpressed CCK2-R.


Subject(s)
Cholecystokinin/analogs & derivatives , Cholecystokinin/chemical synthesis , Pancreatic Neoplasms/metabolism , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/chemistry , Cholecystokinin/chemistry , Humans , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/drug therapy , Receptors, Cholecystokinin/biosynthesis , Receptors, Cholecystokinin/chemistry , Receptors, Cholecystokinin/metabolism
4.
J Med Chem ; 54(20): 7375-84, 2011 Oct 27.
Article in English | MEDLINE | ID: mdl-21928837

ABSTRACT

To achieve early detection and specific cancer treatment, we propose the use of multivalent interactions in which a series of binding events leads to increased affinity and consequently to selectivity. Using melanotropin (MSH) ligands, our aim is to target melanoma cells which overexpress melanocortin receptors. In this study, we report the design and efficient synthesis of new trivalent ligands bearing MSH ligands. Evaluation of these multimers on a cell model engineered to overexpress melanocortin 4 receptors (MC4R) showed up to a 350-fold increase in binding compared to the monomer, resulting in a trivalent construct with nanomolar affinity starting from a micromolar affinity ligand. Cyclic adenosine monophosphate (cAMP) production was also investigated, leading to more insights into the effects of multivalent compounds on transduction mechanisms.


Subject(s)
Dendrimers/chemical synthesis , Melanocyte-Stimulating Hormones/metabolism , Melanoma/metabolism , Peptides/chemical synthesis , Receptor, Melanocortin, Type 4/metabolism , Skin Neoplasms/metabolism , Binding, Competitive , Cyclic AMP/metabolism , Dendrimers/chemistry , Dendrimers/pharmacology , Drug Design , HEK293 Cells , Humans , Ligands , Melanoma/diagnosis , Melanoma/therapy , Peptides/chemistry , Peptides/pharmacology , Receptor, Melanocortin, Type 4/agonists , Receptor, Melanocortin, Type 4/genetics , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL